← Back to Search

Alkylating agents

Lenalidomide for Lymphoma

Phase 1 & 2
Waitlist Available
Led By Jason R. Westin, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 126 days
Awards & highlights

Study Summary

This trial is studying a combination of lenalidomide, obinutuzumab, and CHOP to see if it is safe and effective in treating patients with DLBCL.

Eligible Conditions
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~126 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 126 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD) of Lenalidomide, Obinutuzumab, and CHOP
Secondary outcome measures
Overall Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lenalidomide + Obinutuzumab + CHOPExperimental Treatment6 Interventions
Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles. Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I. Each study cycle is 21 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obinutuzumab
2015
Completed Phase 3
~3250
Cyclophosphamide
1995
Completed Phase 3
~3770
Lenalidomide
2005
Completed Phase 3
~1480
Prednisone
2014
Completed Phase 4
~2370
Vincristine
2003
Completed Phase 4
~2910
Doxorubicin
2012
Completed Phase 3
~7940

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,971 Previous Clinical Trials
1,787,178 Total Patients Enrolled
253 Trials studying Lymphoma
32,501 Patients Enrolled for Lymphoma
CelgeneIndustry Sponsor
636 Previous Clinical Trials
128,912 Total Patients Enrolled
87 Trials studying Lymphoma
9,732 Patients Enrolled for Lymphoma
Genentech, Inc.Industry Sponsor
1,539 Previous Clinical Trials
567,630 Total Patients Enrolled
100 Trials studying Lymphoma
10,601 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
2015. "A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02529852.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top